G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer.
The last earnings update was 56 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
G1 Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
G1 Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
G1 Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
Unable to determine if G1 Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
G1 Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Mark A. Velleca, M.D., Ph.D., has been Chief Executive Officer of G1 Therapeutics, Inc. since May 20, 2014 and has been its President since May 2014. Dr. Velleca served as Senior Advisor at Gilead Sciences, Inc. from 2010 to April 2012, where he worked to help build its oncology pipeline. He was a Co-founder of CGI Pharmaceuticals, Inc. and served as its Senior Vice President from 1999 to 2010. He served as Executive vice president at The Leukemia & Lymphoma Society (LLS) from April 2012 to April 2014. Dr. Velleca joined LLS in 2012 as chief policy and advocacy officer and was responsible for the strategy and implementation of its legislative and regulatory policy initiatives. He served as Vice President of Research and Preclinical Development of CGI Pharmaceuticals, Inc. Dr. Velleca serves as First Employee at CGI and one of its founding scientists. He has more than 15 years of broad-based experience in both basic biomedical research and clinical medicine. He is expertise in the laboratory diagnosis of autoimmune/inflammatory diseases, hematological disorders and cancer, as well as the treatment of cancer patients via stem cell transplantation. He served as Chief Scientific Officer of CGI Pharmaceuticals, Inc. Since CGI's formation, Dr. Velleca has played a leading role in the design and implementation of its scientific strategy for drug discovery and development. He was Chief Resident at Yale New Haven Hospital. He served as a Member of Scientific Advisory Board at BioRelix, Inc from 2007 to 2012. He has been a Director of G1 Therapeutics, Inc. since May 2014. He served as a Director of BioMarker Strategies, LLC from 2010 to 2012. He served as a Member of Scientific Advisory Board of Intellikine, Inc. from 2007 to 2010. Dr. Velleca was on the faculty of Yale Medical School. An attending Physician at Yale New Haven Hospital until 2002, Dr. Velleca maintained an adjunct appointment at Yale University as a Clinical Assistant Professor of Laboratory Medicine. He has published papers in diverse areas of cell and molecular biology, signal transduction, immunology, neuroscience and transfusion medicine. He is the recipient of a NIH Physician/ Scientist Career Award. He is a Board-Certified Clinical Pathologist. Dr. Velleca earned his B.S. Cum Laude from Yale University and is a graduate of the Medical Scientist Training Program at Washington University. He received an M.D. and a Ph.D. in the Neurosciences from Washington University in St. Louis. After completing clinical training at Yale New Haven Hospital, Dr. Velleca did postdoctoral research in Cell Biology and Immunobiology at Yale Medical School.
Mark's compensation has been consistent with company performance over the past year.
Mark's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the G1 Therapeutics management team is less than 2 years, this suggests a new team.
CEO, President & Director
CFO, Senior VP of Corporate Development & Secretary
Senior Vice President of Development Operations
Vice President of Technical Operations
Chief Scientific Officer
VP of Finance & Administration
Head of Investor & Public Relations
Vice President of Quality & Compliance
Head of Human Resources
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the G1 Therapeutics board of directors is about average.
Board of Directors
Chairman of the Board of Directors & Member of Advisory Board
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.